Open an account

Hepion Pharmaceuticals

HEPA · NASDAQ

$0.12+$0.0179 (+17.53%)TodayMarket closed ·
Prev close $0.1021

About HEPA

Hepion Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of drug therapy for treatment of chronic liver diseases. The company is headquartered in Edison, New Jersey. The company went IPO on 2014-02-07. The firm is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.

Employees
22
Headquarters
Edison, New Jersey
Listed
Feb 7, 2014
Sector
Health Care
Industry
Pharmaceuticals
Website
hepionpharma.com

HEPA key statistics

Market cap
11.79M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
41.09K
Volume
18.20K
Open price
$0.134
High today
$0.14
Low today
$0.115
52 Week high
$0.1343
52 Week low
$0.0341

Hepion Pharmaceuticals (HEPA) at a glance

As of Oct 20, 2026, Hepion Pharmaceuticals (HEPA) shares are priced at $0.12, giving the company a market cap of 11.79M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.115 and $0.14. The current price is 4.3% above the day's low and 14.3% below its high.

Volume so far is 18.20K shares, below the average of 41.09K shares a day.

Over the past year Hepion Pharmaceuticals has ranged from $0.0341 to $0.1343, and now sits 86% of the way up that range.

Hepion Pharmaceuticals met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q1 FY25 it reported -$2.15 per share against an estimate of $0.00.

HEPA earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 13.5% on average.

  1. Q2 FY22: reported -$260.00 per share against an estimate of -$122.40
  2. Q3 FY22: reported -$110.00 per share against an estimate of -$173.40
  3. Q4 FY22: reported -$130.00 per share against an estimate of -$132.60
  4. Q1 FY23: reported -$174.00 per share against an estimate of -$183.60
  5. Q2 FY23: reported -$184.00 per share against an estimate of -$169.49
  6. Q3 FY23: reported -$137.00 per share against an estimate of -$159.12
  7. Q4 FY23: reported -$121.00 per share against an estimate of -$134.13
  8. Q1 FY25: reported -$2.15 per share against an estimate of $0.00

HEPA news

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Avi Kapoor

    Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • Avi Kapoor

    Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales

Similar companies

Companies in the same industry as Hepion Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.